01—Abstract
Summary
Summary of the 8-K filed January 7, 2025. Cited figures are marked; the original filing is the authoritative source.
On January 6, 2025, Stryker (SYK) entered into a Merger Agreement to acquire Inari Medical (NARI) for $80.00a per share in cash, implying a fully diluted equity value of approximately $4.9 billion.
The deal is structured as a two-step transaction: a tender offer by a Stryker subsidiary, followed by a Section 251(h) merger to acquire any remaining shares at the same price. Stryker's stated rationale is to expand its portfolio into peripheral vascular disease, particularly venous thromboembolism (VTE), a segment the company describes as high-growth, and to complement its Neurovascular business with Inari's non-thrombolytic mechanical thrombectomy products. Closing is conditioned on a majority minimum tender, expiration or termination of the HSR waiting period, and the absence of legal restraints.
The offer must initially remain open for at least 20 business days and can be extended in 10-business-day increments, with a cap of three extensions where the Minimum Tender Condition is the only unmet condition. The merger agreement's End Date is July 7, 2025, automatically extendable to October 6, 2025 if only regulatory or legal-restraint conditions remain. Inari would owe Stryker a $163 millionb termination fee in specified circumstances, including accepting a superior proposal or a change in its board's recommendation.
Stryker expects the transaction to close by the end of the first quarter of 2025 and will discuss expected impacts on 2025 financial results on its Q4 2024 earnings call on January 28, 2025. For investors, the filing is primarily a deal announcement with limited quantitative disclosure about Stryker's financing, purchase accounting, or pro forma effects. Key items to monitor include the HSR review outcome, tender participation levels, and Stryker's 2025 guidance update, which will indicate how the acquisition is expected to affect earnings and margins.
02—Key points
Key Highlights
- Stryker agreed to acquire Inari Medical for $80.00 per share in cash, approximately $4.9 billion on a fully diluted equity basis.
- Deal structure is a two-step process: a tender offer by a Stryker subsidiary followed by a Section 251(h) merger for untendered shares at the same price.
- Strategic rationale centers on entering the high-growth peripheral vascular segment, particularly venous thromboembolism (VTE), and complementing Stryker's Neurovascular business with non-thrombolytic mechanical thrombectomy products.
- Closing conditions include a majority minimum tender, HSR antitrust clearance, and no legal restraint; the transaction is expected to close by end of Q1 2025.
- Inari faces a $163 million termination fee payable to Stryker if it accepts a superior proposal or its board changes its recommendation.
- The End Date is July 7, 2025, automatically extendable to October 6, 2025 if only regulatory conditions remain outstanding.
- Stryker will provide expected 2025 financial impacts on its Q4 2024 earnings call scheduled for January 28, 2025.
03—Questions
Frequently Asked Questions
How much is Stryker paying for Inari Medical, and how is the deal structured?
Stryker is paying $80.00 per share in cash, implying a total fully diluted equity value of about $4.9 billion. The transaction is a tender offer by a Stryker subsidiary, followed by a second-step merger under DGCL Section 251(h) to acquire any shares not tendered, at the same price.
When is the deal expected to close, and what could delay it?
Stryker expects closing by the end of the first quarter of 2025. Potential delays include failure to achieve the majority minimum tender, a longer HSR antitrust review (which may come with conditions), or legal challenges. The tender offer must stay open at least 20 business days and may be extended in 10-business-day increments.
What protections exist if Inari receives a competing bid?
Inari agreed to no-shop restrictions but may engage with unsolicited proposals that its board deems superior. If Inari terminates to accept a superior proposal, or if its board changes its recommendation, Inari must pay Stryker a $163 million termination fee.
What strategic value does Inari bring to Stryker?
Inari adds a leading position in peripheral vascular care, focused on VTE treatment, including mechanical thrombectomy for deep vein thrombosis and pulmonary embolism without thrombolytic drugs. Stryker characterizes the segment as fast-growing and complementary to its Neurovascular franchise.
What financial impact should investors expect for 2025?
The filing does not quantify the impact on 2025 results. Stryker stated it will discuss expected impacts during its Q4 2024 earnings call on January 28, 2025, which investors should review for guidance on earnings, margins, and financing effects.
04—Continue